Since the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7), invasive infections caused by Streptococcus pneumoniae have declined in children in the United States. [1] [2] [3] [4] The Centers for Disease Control and Prevention (CDC) reported a 77% reduction in rates of invasive pneumococcal disease among children Ͻ5 years of age when comparing the pre-PCV7 years 1998 -1999 to the post-PCV7 year 2005 in their 8-state Active Bacterial Core surveillance system. 5 However, the CDC and several groups have found that the number of pneumococcal infections caused by serotypes not found in the PCV7, primarily serotype 19A, is increasing. [6] [7] [8] [9] [10] [11] [12] In addition, multidrug antibiotic resistance among the 19A serotype isolates, related to several different clonal types, has become a major issue. 6, 10, 11, 13 Investigators from 8 children's hospitals have conducted prospective surveillance of invasive pneumococcal infections among children seen at their hospitals since September 1993. In this report, surveillance results for the full years 1994 -2008 are described.
METHODS
The US Pediatric Multicenter Pneumococcal Surveillance Group consists of investigators from 8 children's hospitals who have been prospectively identifying children treated as inpatients or outpatients at their centers for invasive infections caused by S pneumoniae beginning in September 1993. 3 The dates of surveillance for this report include the period January 1, 1994, through December 31, 2008. The study was approved and informed consent was waived by the institutional review boards of each of the participating hospitals.
Systemic infections were documented by positive culture results from a normally sterile site (blood, cerebrospinal fluid, pleural fluid, synovial fluid, peritoneal fluid, etc). The diagnosis of pneumococcal pneumonia required a chest radiograph showing pulmonary infiltrates, in addition to a positive culture result from blood, pleural fluid, or the lung. Mastoiditis was also considered an invasive infection, for which isolates were obtained from either middle-ear fluid or mastoid bone. The approach to obtaining blood cultures from febrile children without a focus was not uniform among the 8 children's hospitals. Demographic and clinical information was collected retrospectively and recorded on a standard case report form for each episode of infection. After licensure of PCV7 in February 2000, documentation of administration of PCV7 was sought through the medical charts or by contacting the patient's physician. 
RESULTS
After the introduction of PCV7 in spring of 2000, the number of invasive infections decreased yearly, from an average of 426 cases per year for the pre-PCV7 period (1994 -2000) to a low of 151 cases in 2004 (Fig 1) . This represented a 65% decline in cases in all age groups by 2004 compared with the av- 
FIGURE 1
Number of invasive pneumococcal infections (y-axis) in children among 8 children's hospitals according to study years (x-axis) from 1994 to 2008. PCV7 was introduced in 2000.
erage of the 7 years immediately preceding the introduction of PCV7. The decline among children in the 1-yearold age group was striking (Fig 2) . However, the overall number of cases increased from 2005 through 2008, in which 204 cases occurred (Fig 1) 
Sites of Infection
The proportion of cases that involved pneumococcal bacteremia without a source decreased from 56% (1658 of 2987) of cases before the PCV7 to 42% (621 of 1490) after the PCV7 (P Ͻ .001). In contrast, pneumonia accounted for an increasing proportion of cases after the PCV7 (28% [419 of 1490]) versus before the PCV7 (20% [606 of 2987]; P Ͻ .001). Bacterial meningitis accounted for a relatively stable proportion throughout the years (11%-17%; see Fig 9 , which is published as supporting information at www.pediatrics.org/content/full/125/3/ 429).
When focusing on sites of infection for nonvaccine isolates after 2000, pneumonia accounted for more than 80% (47 of 58) of cases for serotype 1 and 53% (45 of 85) of cases for serotype 3 (Fig 4) . For 19A isolates, 33% (135 of 415) of cases were pneumonia. Meningitis accounted for 20% (55 of 282) of the infections caused by the combined serotypes 6A, 7F, 22, and serogroups 15 and 33, which was twice the proportion for the other more common nonvaccine serotypes.
Underlying Conditions
In the pre-PCV7 years, an underlying condition was noted in an average of 30% of children each year (range: 28%-36%). This percentage has increased since 2000, reaching Ͼ41% of patients in 2006. The types and relative frequencies of underlying conditions for the pre-and post-PCV7 years are shown in Table 2 . Of the children with underlying diseases, the proportion that had malignancies increased 44% for the post-PCV7 years (127 of 552 (Table 6 , which is published as supporting information at www.pediatrics.org/content/full/ 125/3/429). Serotypes 19A (P ϭ .002) and 3 (P Ͻ .001) and serogroup 33 (P ϭ .005) accounted for a greater proportion of isolates among the children without underlying conditions compared with children who had an underlying condition, whereas the opposite was true for serotype 6A (P ϭ .001) and serogroup 15 (P ϭ .004).
Antibiotic Susceptibilities
Rates of resistance to erythromycin declined and clindamycin resistance rates were stable until 2004 when the rates for both began to increase, primarily because of the increase in serotype 19A isolates (Fig 5) . 0.015 g/mL, whereas for the 19A isolates, the MIC 90 and mode MICs were 1.0 g/mL, and the median MIC was 0.06 g/mL.
In 2007 and 2008, serotype 19A isolates were significantly more resistant than non-19A isolates to erythromycin, clindamycin, or trimethoprimsulfamethoxazole (P Ͻ .001 for each; Table 3 ). In addition, 54% of the serotype 19A isolates (91 of 168) were nonsusceptible to erythromycin, clindamycin, and trimethoprim-sulfamethoxazole. Of these 91 isolates, 39 had a penicillin MIC of 2 g/mL, 48 had a penicillin MIC of 4 g/mL, 3 had a penicillin MIC of 8 g/mL, and 1 had a penicillin MIC of 0.06 g/mL. For these 91 isolates, the distribution of ceftriaxone MICs was 1 for 0.03 g/mL, 72 for 1.0 g/mL, 13 for 2.0 g/mL, 3 for 4 g/mL, and 2 for 8 g/mL. Thus, 30% (51 of 168) of the serotype 19A isolates were multidrug resistant in 2007 and 2008.
PCV7 Doses and Invasive Pneumococcal Infection
For each of the years from 2004 to 2008, the number of PCV7 doses children had received before their episode of invasive pneumococcal infection was significantly associated with the likelihood that their isolate was a serotype 19A (Table 4) . To determine if this association was related to age, we found that for children Ͻ5 years old, there was no significant association between age in years and proportion of isolates that were serotype 19A, except for 2005, in which the proportion of 19A isolates decreased with age (Table 5) .
DISCUSSION
After the introduction of the 7-valent pneumococcal conjugate vaccine in the United States, a number of investigators reported marked declines in invasive pneumococcal infection in children as well as in people of other age groups who were not immunized. [1] [2] [3] [4] [5] However, within a very short time after the introduction of the PCV7, disease caused by nonvaccine serotypes, especially serotype 19A, emerged as a growing concern. The results of our study confirm and extend the degree to which serotype 19A has caused inva- 
FIGURE 6
The number of invasive pneumococcal isolates per penicillin MIC for isolates recovered from children at 8 children's hospitals in 2007 and 2008: 19A versus non-19A isolates.
FIGURE 7
The The proportion of invasive pneumococcal cases that were bacteremia alone declined but increased for pneumonia after the availability of PCV7 compared with cases before PCV7 use. Several studies have shown that in the post-PCV7 era, pneumococcal bacteremia has not been commonly detected in young children who have fever without a focus. [18] [19] [20] [21] In contrast, the frequency of complicated pneumonias caused by non-PCV7 serotypes has increased in some areas of the United States. 22 Serotypes 1, 3, and 7F also were important nonvaccine serotypes in our study and collectively accounted for 21% of the nonvaccine serotype isolates in 2007 and 2008. The numbers of isolates each year for serotypes 1 and 3 have been stable, whereas the 7F isolates seem to be on the rise. The majority of the infections caused by serotypes 1 and 3 isolates were pneumonia; ϳ30% of 19A and 7F isolates were associated with pneumonia. Serotype 19A also had a unique association with acute mastoiditis in 1 study. 17 Other notable serotypes or serogroups after 2001 were 6A, 15, 22, and 33.
As the number of children who have received PCV7 has increased and with a subsequent decline in invasive infections, the proportion of children with an underlying condition among children who have invasive pneumococcal infections has increased. Although the average yearly number of children with invasive pneumococcal infection and an underlying condition has decreased from 128 in the 7-year pre-PCV7 period compared with 69 over the 8 years after the PCV7, the underlying condition of malignancy was reduced the least relative to the other conditions. Perhaps the immunosuppression associated with malignancies is greater than that for the other underlying conditions. The serotype distribution was somewhat different for children with or without an underlying condition.
We chose to present the MICs for penicillin and ceftriaxone for 2007 and 2008 because these data really demonstrated the differences between serotype 19A and non-19A serotypes for these antibiotics. The use of the 2009 CLSI interpretive break points for susceptible, intermediate, and resistant to compare the penicillin and ceftriaxone susceptibilities blunts these differences substantially, considering the 2008 modifications for penicillin interpretive break points for nonmenin- In our study, for the children who had an invasive pneumococcal infection, the number of PCV7 doses received before they developed that invasive pneumococcal infection correlated with having a serotype 19A isolated over each of the years from 2004 to 2008. These findings would support that in the United States, emergence of serotype 19A as the most common pneumococcal serotype causing invasive infections in children is related, at least in part, to the routine administration of PCV7 to infants and children. As more doses of PVC7 are administered, it is possible that there is a greater decline in carriage of vaccine serotypes, as seen in a study from the Netherlands in which 2 doses given at 2 and 4 months and 3 doses of PCV7 given at 2, 4, and 11 months were compared. 27 Nonvaccine serotype carriage was increased slightly at 24 months of age for children in the 3-dose group (43%) compared with those in the 2-dose group (40%), although this difference was nonsignificant. Compared with control children not receiving PCV7, 19A was the only serotype that was significantly increased in frequency of carriage for either the 2-or 3-dose regimens. So, it is possible that 19A nasopharyngeal carriage increases as more PCV7 doses are administered. This might result in a greater proportion of invasive isolates being 19A in children as the number of PVC7 doses increases among those children with invasive disease. Clearly, 19A has a greater ability to cause invasive disease than other non-PCV7 serotypes for reasons that are yet to be determined.
Our study was limited in that it was case based and not population based. However, the annual number of 19A isolates increased significantly over the years 2001-2008 compared with the total number of annual admissions for the 8 children's hospitals in this study over the same period. In addition, the combined annual admissions to our 8 children's hospitals increased 9% in 2008 compared with a 35% increase in invasive cases in these same years. Our study was also limited to only children's hospitals, so the population of children studied may be biased compared with all children with invasive infection. All information regarding receipt of the PCV7 may not have been ascertained; information regarding previous antibiotic administration was not collected. Furthermore, 4% of isolates were not available for typing.
CONCLUSIONS
In addition to the 7 serotypes in the current PCV7, serotypes 1, 3, 5, 6A, 7F, and 19A are included in a 13-valent pneumococcal conjugate vaccine under development. 28 For 2007 and 2008, these 6 additional serotypes accounted for 252 (68%) of 369 isolates that were non-PCV7 serotypes. Presumably, the 13-valent pneumococcal conjugate vaccine should be associated with an additional reduction in invasive pneumococcal infections in children, but continued surveillance will be required to document the impact of the expanded pneumococcal conjugate vaccine and to detect the emergence of new serotypes.
